JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beauchesne, P.
Right arrow Articles by Soler, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beauchesne, P.
Right arrow Articles by Soler, C.

99mTc-Sestamibi Brain SPECT After Chemoradiotherapy Is Prognostic of Survival in Patients with High-Grade Glioma

Patrick Beauchesne, MD, PhD1,2, Remy Pedeux, PhD1, Mathieu Boniol, MS1 and Claude Soler, MD3

1 Institut National de la Santé et de la Recherche Médicale, Unité 453, Centre Léon Bérard, Lyon, France
2 Service de Neurochirurgie, Centre Hospitalier Universitaire, Saint-Etienne, France
3 Centre d’Imagerie Nucléaire, Saint-Etienne, France



View larger version (10K):

[in a new window]
  		FIGURE 1. Cumulative survival according to tumor volume at the end of radiotherapy. The graph represents the cumulative MST (according to tumor volume) of the population at the end of radiotherapy. Patients with a tumor volume < 32 cm3 had an MST of 358 d, vs. 238 d in patients with a tumor volume >= 32 cm3.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.